SBIR-STTR Award

Instrument To Characterize Cell-Free 02 Carriers
Award last edited on: 7/2/08

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$105,359
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Kim Vandegriff

Company Information

Sangart Inc

6175 Lusk Boulevard
San Diego, CA 92121
   (858) 450-2400
   sangartinfo@sangart.com
   www.sangart.com
Location: Multiple
Congr. District: 52
County: San Diego

Phase I

Contract Number: 1R43HL063577-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1999
Phase I Amount
$105,359
A new instrument to characterize O2 transport by cell-free hemoglobin and/or mixtures of cell-free hemoglobin and red blood cells has been invented, and a patent has been applied for. This instrument measures diffusional O2 transport using a small sample, and is applicable both to the development of cell-free hemoglobin solutions and to monitoring patients who have received them. The goal of this proposal is to optimize the design of this instrument to measure O2 transport by cell-free hemoglobin solutions in vitro using an artificial capillary system. Under Specific Aim 1, we will build an artificial capillary system to assess O2 transport by cell- free hemoglobin solutions in vitro. We will optimize the breadboard design of our present artificial capillary instrument. Measurements of O2 transport will be made using cell-free hemoglobin solutions, including model solutions of PEG-hemoglobin and cross-linked tetrameric hemoglobin, and RBC suspensions. Under Specific Aim 2, we will automate the capillary apparatus and further develop software for data interpretation. The data- analysis model uses mathematical concepts based on the Krogh cylinder model for O2 transport out a cylindrical tube of defined geometry (i.e., the artificial capillary). This programs requires 1) optimization for run time efficiency and 2) testing against experimental data from hemoglobin solutions and/or red blood cells in the artificial capillary device. The hypothesis underlying this proposal is that a new method to assess O2 transport by cell-free oxygen carriers is required before candidate products can be evaluated accurately. This is due to the phenomenon of facilitated diffusion of O2 in the presence of cell-free carriers, which can lead to autoregulatory vasoconstriction. PROPOSED COMMERCIAL APPLICATIONS: Methods of clinical evaluation of O2 transport (Hb, Het) in the presence of cell-free oxygen carriers are inadequate. We have invented a new instrument to characterize O2 transport by cell-free hemoglobin that includes evaluation of facilitated diffusion. This instrument has great potential for clinical measures in patients who have received hemoglobin- based products, as well as potential in the testing of new candidate solution.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----